Overview
Pharmaceutical

BrightPath Biotherapeutics Co.,Ltd.

Brightpath Bio is a clinical-stage oncology drug discovery venture focused exclusively on the development of novel cancer immunotherapies. The company's pipeline encompasses three modalities: cell therapies (including iPS cell-derived NKT cell therapies and CAR-T cell therapies), antibody drugs targeting immune checkpoint and immunomodulatory factors, and cancer vaccines. Its business model centers on in-house discovery and early-stage clinical development of cancer immunotherapy candidates, followed by licensing to domestic and international pharmaceutical companies in exchange for upfront payments, development milestones, and sales royalties.

Market Cap
¥5.42B
US$34.5M
EV
¥3.84B
US$24.5M
Stock¥39▼-2.50%
US$1 = ¥156.80 (2026-10-23)
LTM EV/EBITDA
—
LTM EV/EBIT
NM
LTM PER
NM
LTM PBR
3.0
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-62.2%pt
1001234
Oct 24, 25 – Oct 23, 26StockTOPIX
1Feb 18, 26Positive biotech sector news
2Mar 24, 26Biotech sector uptrend momentum
3Mar 25, 26Continuation of previous day's momentum
4Mar 26, 26Profit-taking following recent gains
MC → EV Bridge
5.42BUS$34.5MMarket Cap0.00BUS$0.00M+ Debt1.58BUS$10.1M− Cash0.00BUS$0.00M− Inv. Sec.3.84BUS$24.5MEV
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
0.02US$0.10M'22/30.01US$0.03M'23/30US$0.00M'24/30.00US$0.01M'25/30US$0.00M'26/3
EBITDA 5Y (¥B)
-1.44-US$9.19M'22/3-1.45-US$9.25M'23/3-1.15-US$7.36M'24/3-1.16-US$7.40M'25/3
Net Income 5Y (¥B)
-1.48-US$9.46M'22/3-1.49-US$9.47M'23/3-1.17-US$7.45M'24/3-1.15-US$7.34M'25/3-1.30-US$8.32M'26/3
Capital Structure
100%
EquityD/E 0.00xDebt
Liquidity vs Debt 5Y (¥B)▲ Net Cash
CashInv. Sec.Debt
2.31US$14.7M'22/31.53US$9.76M'23/31.06US$6.74M'24/30.81US$5.17M0.03US$0.16M'25/32.16US$13.8M'26/3
Shareholders
Top 10 hold 12.9%
1
Rakuten Securities, Inc. (Joint Account)
2.47%
2
SBI SECURITIES Co., Ltd.
2.46%
3
Ueda Yagi Tanshi Co., Ltd.
2.01%
4
BNYM SA/NV FOR BNYM FOR BNY GCM CLIENT ACCOUNTS M LSCB RD
1.33%
5
Japan Securities Finance Co.,Ltd.
1.04%
6
MATSUI SECURITIES CO.,LTD.
1.04%
7
Monex, Inc.
0.82%
8
Hiroya SENO
0.71%
9
Mitsubishi UFJ eSmart Securities Co., Ltd.
0.57%
10
GMO CLICK Securities, Inc.
0.47%
Management
6 officers
Kenichi NAGAI
Representative Director, President
Apr 1994 Joined EDS Japan K.K. Aug 1996 Joined Merrill Lynch Japan Securities Co., Ltd., Investment Banking Division Apr 2005 Director, CFO and General Manager of Administration Division, Perseus Proteomics Inc. Jan 2009 Director, CFO and General Manager of Administration Division, the Company Mar 2011 Representative Director, President, the Company (current) Dec 2016 Representative Director, President, Advanced Immunotherapeutics Inc. Mar 2019 Outside Director, KORTUC Inc.
1970-05-15
Ryo YAMADA
Director
Apr 1995 Lecturer, Department of Immunology, School of Medicine, Kurume University May 2000 Associate Professor, Department of Immunology, School of Medicine, Kurume University May 2003 Founded the Company; Representative Director Dec 2003 Professor, Advanced Cancer Translational Research Center, Kurume University Jan 2004 Director, the Company (current) Apr 2016 Director, Advanced Cancer Translational Research Center, Kurume University Apr 2022 Special Appointed Professor / Professor Emeritus reporting directly to the President, Kurume University (current) Apr 2022 Advisor, Japanese Society for Cancer Immunology (current)
1957-03-11
Hirotaka TAKEUCHI
Director
Apr 1969 Joined McCann-Erickson Hakuhodo Inc. (now McCann Erickson Japan Inc.) Sep 1976 Lecturer, Harvard Business School Dec 1977 Associate Professor, Harvard Business School Apr 1983 Associate Professor, Faculty of Commerce, Hitotsubashi University Apr 1987 Professor, Faculty of Commerce, Hitotsubashi University Apr 1998 Dean, Graduate School of International Corporate Strategy, Hitotsubashi University Apr 2008 Outside Director, Integral Inc. (current) Apr 2010 Professor Emeritus, Hitotsubashi University (current) Jul 2010 Professor, Harvard Business School Jun 2015 Outside Director, the Company (current) Jun 2016 Outside Director, Daiwa Securities Group Inc. Jun 2019 Chairman of the Board of Trustees, International Christian University (current)
1946-10-16
Tsutomu KISHINO
Full-time Corporate Auditor
Apr 1977 Joined Japan Development Bank (now Development Bank of Japan Inc.) Mar 1992 Visiting Researcher, Brookings Institution (USA) Mar 1993 Senior Researcher, Institute of Capital Investment Research, Japan Development Bank Apr 1997 Director, Toyama Office, Japan Development Bank Jun 1999 Chief Representative, New York Office, Japan Development Bank Jun 2002 Branch Manager, Hokuriku Branch, Development Bank of Japan Inc. Jun 2004 Managing Director, Ikebukuro District Heating and Cooling Co., Ltd. Jun 2016 Senior Managing Director, Ikebukuro District Heating and Cooling Co., Ltd. Jun 2017 Representative Director, Senior Managing Director, Ikebukuro District Heating and Cooling Co., Ltd. Aug 2018 Director, Japan Medical Research Center (general incorporated association) Jun 2019 Outside Corporate Auditor, the Company (current)
1953-01-28
Takeshi ABE
Corporate Auditor
Apr 1969 Joined Sankyo Co., Ltd. (now Daiichi Sankyo Company, Limited) Apr 2001 General Manager, Legal Affairs Department, Sankyo Co., Ltd. Feb 2005 Joined PostGenome Institute Co., Ltd. Apr 2005 Joined Sankyo Chemical Industry Co., Ltd. Mar 2006 Corporate Auditor, PostGenome Institute Co., Ltd. Jun 2009 Outside Corporate Auditor, the Company (current)
1944-01-29
Yoshiyasu YAMAGUCHI
Corporate Auditor
Apr 1988 Joined Yamaichi Securities Co., Ltd. Apr 1989 Entered Legal Training and Research Institute of the Supreme Court of Japan Apr 1991 Registered with Tokyo Bar Association; joined TMI Associates Sep 1997 Seconded to Eisai Inc. (USA), Legal Department Jun 1998 Registered as attorney in New York State Jun 1998 Seconded to Simmons & Simmons (UK) Apr 1999 Partner, TMI Associates (current) Jun 2015 Outside Corporate Auditor, the Company (current)
1964-02-12
Large Shareholding Reports
Phillip Capital Securities Co., Ltd.
2026-10-07
19.90%
Phillip Securities Japan, Ltd.
2026-02-19
6.29%→4.88%
Phillip Securities Japan, Ltd.
2026-01-29
7.29%→6.29%
Phillip Securities Japan, Ltd.
2026-01-21
9.24%→7.29%
Phillip Securities Japan, Ltd.
2026-01-20
18.94%→9.24%
Phillip Securities Japan, Ltd.
2026-01-06
19.80%→18.70%
Phillip Securities Japan, Ltd.
2025-12-29
19.80%→18.94%
Phillip Securities Japan, Ltd.
2025-12-18
19.80%→19.57%
Phillip Securities Japan, Ltd.
2025-12-18
24.68%→19.80%
Phillip Securities Japan, Ltd.
2025-12-17
24.68%→24.32%
Phillip Securities Japan, Ltd.
2025-12-17
24.68%
Disclosures
No disclosures
Primary Source Filings
EDINET
2026-10-07
Large Shareholding Report
EDINET
2026-09-18
Securities Registration Statement
TDnet
2026-08-14
Q1 Earnings Flash
FY ending Mar 2027
EDINET
2026-06-25
Annual Securities Report
Period: Apr 2025 – Mar 2026
EDINET
2026-02-19
Large Shareholding Report
TDnet
2026-02-13
Q3 Earnings Flash
FY ending Mar 2026
EDINET
2026-01-29
Large Shareholding Report
EDINET
2026-01-21
Large Shareholding Report
EDINET
2026-01-20
Large Shareholding Report
EDINETAmended
2026-01-06
Change Report
EDINET
2026-01-06
Large Shareholding Report
EDINETAmended
2025-12-18
Change Report
EDINETAmended
2025-12-18
Change Report
EDINET
2025-12-17
Large Shareholding Report
EDINET
2025-12-17
Large Shareholding Report
EDINET
2025-11-21
Securities Registration Statement
EDINET
2025-11-14
Semi-Annual Securities Report
Period: Apr 2025 – Mar 2026
TDnet
2025-08-08
Q1 Earnings Flash
FY ending Mar 2026
EDINET
2025-06-19
Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2025-02-14
Q3 Earnings Flash
FY ending Mar 2025
EDINET
2024-11-08
Semi-Annual Securities Report
Period: Apr 2024 – Mar 2025
TDnet
2024-08-09
Q1 Earnings Flash
FY ending Mar 2025
EDINET
2024-06-21
Annual Securities Report
Period: Apr 2023 – Mar 2024
EDINETAmended
2024-06-21
Amended Securities Registration Statement
EDINET
2024-06-19
Securities Registration Statement
EDINET
2024-02-09
Quarterly Securities Report
Period: Oct 2023 – Dec 2023
EDINETAmended
2023-11-15
Amended Securities Registration Statement
EDINET
2023-11-14
Securities Registration Statement
EDINET
2023-11-10
Quarterly Securities Report
Period: Jul 2023 – Sep 2023
EDINET
2023-08-10
Quarterly Securities Report
Period: Apr 2023 – Jun 2023
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →